Symptomatology and General Principles of Treatment of Chronic Hepatitis
1. Kebekova Aizat Ashimzhanovna
2. Singh Khushi
3. Hainal Neha
(1. Lecturer, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
3. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic)
Abstract
Chronic hepatitis is a diffuse inflammatory disease of the liver lasting more than six months. It is caused by viral, autoimmune, metabolic, toxic, and drug-induced mechanisms. The disease often progresses silently and may lead to cirrhosis, liver failure, and hepatocellular carcinoma. This article reviews the aetiology, clinical symptomatology, laboratory and instrumental findings, and the general principles of treatment of chronic hepatitis, with emphasis on aetiological therapy and the monitoring of complications.
Keywords: chronic hepatitis, hepatitis B, hepatitis C, autoimmune hepatitis, symptomatology, antiviral therapy, fibrosis, cirrhosis
1. Introduction
Chronic hepatitis is defined as hepatocellular necrosis and inflammation persisting for at least six months, with or without fibrosis. It is a major global health problem. According to the World Health Organization, chronic viral hepatitis B and C together affect hundreds of millions of people worldwide and are among the leading causes of cirrhosis and liver cancer. In many countries, including those of Central Asia, hepatitis B, C, and D remain highly relevant, while metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease are increasingly common. Because early disease is frequently asymptomatic, many patients are diagnosed late. Knowledge of the clinical picture and of modern treatment principles is therefore essential for every physician.
2. Aetiology and Classification
Chronic hepatitis is classified today mainly by cause, then by grade of necroinflammatory activity and stage of fibrosis. Chronic hepatitis is defined by ongoing inflammatory and necrotic injury within the liver parenchyma lasting for more than six months, arising from a diverse group of etiologies that vary widely in their underlying pathophysiological mechanisms.
Viral infections represent a major primary cause of chronic hepatitis worldwide, led predominantly by hepatitis B virus (HBV) and hepatitis C virus (HCV). Hepatitis D virus (HDV) acts as a dependent pathogen, occurring exclusively as a co-infection or superinfection alongside hepatitis B and significantly accelerating parenchymal destruction. While hepatitis E virus typically causes self-limiting acute infections, it can progress to chronic hepatitis in immunosuppressed individuals, such as solid organ transplant recipients or patients undergoing intensive chemotherapy.
Autoimmune hepatitis (AIH) develops as a chronic, progressive inflammatory condition driven by a loss of immune tolerance to hepatocyte autoantigens. T-cell-mediated destruction leads to ongoing interface hepatitis, elevated systemic hypergammaglobulinemia, and specific circulating autoantibodies, requiring long-term immunosuppressive management to halt progression to cirrhosis.
Metabolic and fatty liver diseases have become increasingly prevalent contributors to chronic hepatic inflammation. Metabolic dysfunction-associated steatotic liver disease (MASLD) begins with simple lipid accumulation inside hepatocytes, but can progress to metabolic dysfunction-associated steatohepatitis (MASH). In MASH, persistent lipotoxicity triggers reactive oxygen species, cellular ballooning, and chronic inflammatory cell infiltration that gradually destabilizes liver architecture.
Alcohol-related hepatitis arises from continuous ethanol misuse, where toxic metabolites such as acetaldehyde cause direct oxidative damage and cellular stress. This metabolic disruption leads to continuous inflammatory cascades, Mallory-Denk body formation, and severe pericellular fibrosis.
Drug-induced and toxic liver injury occurs when prolonged exposure to therapeutic agents or environmental toxins causes direct hepatocellular toxicity or secondary immune-mediated reactions. Long-term administration of drugs such as methotrexate, amiodarone, or nitrofurantoin can induce persistent low-grade necroinflammation that mimics viral or metabolic hepatitis.
Hereditary and metabolic disorders contribute to chronic inflammation through the progressive accumulation of pathological substances inside hepatic tissue. In Wilson disease, defective biliary copper transport results in toxic intracellular copper accumulation. Alpha-1 antitrypsin deficiency causes misfolded mutant proteins to accumulate within the endoplasmic reticulum of hepatocytes. Hereditary hemochromatosis leads to systemic iron overload with massive parenchymal deposition, generating continuous free-radical damage and tissue necrosis.
When exhaustive diagnostic testing fails to identify an established viral, autoimmune, metabolic, or toxic etiology, the condition is categorized as cryptogenic chronic hepatitis. Many cases historically classified as cryptogenic are now recognized as late-stage MASH, where intracellular fat accumulation has diminished over time as extensive fibrosis alters the underlying tissue structure.
By activity and stage: Activity (grade) reflects the intensity of necrosis and inflammation, and stage reflects the degree of fibrosis, from F0 (none) to F4 (cirrhosis), for example on the METAVIR scale.
3. Pathogenesis in Brief
In viral hepatitis, the virus is not always directly cytopathic. Liver injury results mainly from the immune response of cytotoxic T-lymphocytes against infected hepatocytes. Persistent inflammation activates hepatic stellate cells, which produce collagen and cause progressive fibrosis. In autoimmune hepatitis, loss of tolerance to hepatocyte antigens produces immune-mediated injury. In metabolic and alcoholic disease, lipotoxicity, oxidative stress, and inflammatory cytokines drive hepatocyte damage. The common end point is architectural distortion, regenerative nodules, and cirrhosis.
4. Symptomatology
4.1 General features
The clinical picture depends on the cause, the degree of activity, and the stage of fibrosis. Mild disease may be completely asymptomatic and discovered by raised transaminases on routine testing. Symptoms are usually non-specific and correlate poorly with histological severity.
4.2 Main complaints
The clinical presentation of chronic hepatitis encompasses a wide array of systemic, gastrointestinal, and extrahepatic manifestations that reflect ongoing hepatocellular inflammation and impaired metabolic function.
Systemic and constitutional symptoms dominate the early presentation of chronic hepatitis, with fatigue, generalized physical weakness, reduced work capacity, and sleep disturbances representing the most universal patient complaints. These persistent features stem from impaired hepatic energy metabolism, altered neurotransmitter clearance, and the systemic activity of circulating pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukins released during ongoing parenchymal injury.
Abdominal discomfort is localized primarily to the right hypochondrium, presenting as a constant, dull ache or a sensation of heavy fullness. This discomfort is typically exacerbated following the ingestion of fatty or rich foods, alcohol consumption, or vigorous physical exertion. The physiological mechanism behind this pain relates directly to localized hepatic swelling, which stretches the nerve-innervated visceral Glisson's capsule surrounding the liver.
Gastrointestinal and dyspeptic disturbances reflect secondary digestive dysmotility and altered bile secretion. Patients frequently experience anorexia, early satiety, nausea, flatulence, and postprandial bloating. A characteristic bitter taste in the mouth and persistent intolerance to fatty foods arise from quantitative or qualitative alterations in bile acid flow reaching the duodenum, impairing normal lipid digestion and intestinal transit.
Systemic inflammatory markers and extrahepatic autoimmune involvement can manifest across several organ systems during active disease flares. Sustained low-grade fever frequently accompanies periods of heightened necroinflammatory activity within the hepatic lobules. Furthermore, extrahepatic immunologic phenomena produce persistent joint pain (arthralgia) and muscle aches (myalgia), which are particularly prominent in chronic viral infections like hepatitis C and in autoimmune hepatitis due to circulating immune complex deposition.
Excretory failure and cholestatic symptoms mark exacerbations of active disease or structural biliary involvement. Mild or transient jaundice, accompanied by dark tea-colored urine and pale, clay-colored stools, signifies impaired bilirubin conjugation or canalicular transport. When chronic inflammation primarily targets the intrahepatic bile ducts, systemic retention of bile salts and pruritogenic mediators triggers severe pruritus, leading to secondary excoriations from persistent skin itching.
4.3 Physical examination
Physical examination findings in chronic hepatitis reflect the extent of parenchymal inflammation, structural liver remodeling, endocrine dysregulation, and the emergence of portal hypertension.
Palpation of the abdomen provides direct assessment of organomegaly and tissue consistency. Hepatomegaly is a frequent finding, presenting with a firm, smooth, and slightly tender liver edge on deep inspiration, resulting from chronic cellular infiltration and passive capsular stretching. Detection of splenomegaly signals the progression from simple lobular inflammation to advanced structural remodeling, marking the development of elevated intrahepatic vascular resistance and early portal hypertension.
Cutaneous and ocular signs reflect underlying bilirubin clearance capacity and systemic vascular changes. Scleral icterus and overt jaundice of the skin emerge during acute inflammatory flares or advanced disease states, indicating significant hepatocyte dysfunction or canalicular cholestasis.
Extrahepatic stigmata of chronic liver disease arise primarily from altered steroid hormone metabolism and vascular hyperreactivity. Impaired hepatic clearance of circulating estrogens alters the systemic estrogen-to-androgen ratio, manifesting as spider angiomata over the upper trunk and face, palmar erythema over the hypothenar and thenar eminences, gynecomastia, testicular atrophy, and a sparse distribution of axillary and pubic body hair. Additionally, cutaneous purpura and ecchymoses develop due to reduced hepatic synthesis of clotting factors paired with platelet sequestration from splenomegaly.
In decompensated states, physical examination reveals overt fluid retention, collateral venous shunting, sarcopenia, and neurological impairment. Severe portal hypertension paired with hypoalbuminemia drives third-space fluid accumulation, manifesting as tense ascites with shifting dullness and dependent peripheral edema. Recanalization of the umbilical vein decompression pathway yields visible tortuous abdominal wall veins radiating from the umbilicus, known as caput medusae. Systemic hypermetabolism and nutrient malabsorption cause progressive temporal and limb muscle wasting, while neurotoxic accumulation precipitates asterixis—a sharp, intermittent loss of motor tone visible as a flapping tremor of the outstretched hands—confirming the presence of hepatic encephalopathy.
4.4 Clinical syndromes
The clinical evaluation of chronic hepatitis and progressive liver disease relies on grouping laboratory, physical, and functional abnormalities into distinct pathological syndromes. These six core syndromes reflect specific cellular mechanisms of damage, structural remodeling, and organ dysfunction, providing a structured framework for differential diagnosis and therapeutic monitoring.
Cytolytic syndrome serves as the primary biochemical indicator of direct hepatocyte injury and cell membrane destruction. Microscopic damage to liver cells leads to the leakage of intracellular enzymes into the systemic circulation, manifesting clinically as elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The degree of transaminase elevation correlates directly with the acute intensity of lobular and interface necroinflammation, guiding the assessment of active parenchymal necrosis.
Cholestatic syndrome results from impaired bile formation, secretion, or flow at the microscopic canalicular or macroscopic ductal levels. Mechanistically, intracellular accumulation or mechanical obstruction of bile components causes serum retention of biliary enzymes and excreted substances. Clinically, this presents with jaundice, systemic pruritus, dark urine, and pale stools, complemented by elevated serum alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and total or conjugated bilirubin levels.
Mesenchymal-inflammatory syndrome reflects immunologic activation within the hepatic stroma, reticuloendothelial system, and interlobular connective tissue. Continuous antigen stimulation drives systemic immune responses, leading to hypergammaglobulinemia, elevated total serum immunoglobulin levels (IgG, IgM, IgA), and altered protein stability tests such as the thymol turbidity test. In autoimmune or chronic viral conditions, this syndrome is further characterized by circulating autoantibodies, including antinuclear antibodies (ANA), smooth muscle antibodies (SMA), or anti-liver kidney microsome type 1 (anti-LKM-1) antibodies.
Hepatocellular insufficiency syndrome quantifies the functional loss of viable liver cell mass and diminished metabolic capacity. As healthy hepatocytes are replaced by fibrotic tissue, the liver loses its ability to synthesize vital plasma proteins and clear endogenous substrates. Laboratory parameters reveal hypoalbuminemia, a prolonged prothrombin time with an elevated International Normalized Ratio (INR), reduced serum cholinesterase activity, and decreased total cholesterol levels. Clinically, this synthetic failure manifests as peripheral fluid retention, profound metabolic dysregulation, and an increased bleeding tendency due to depleted coagulation factors.
Portal hypertension syndrome arises from structural distortion of the hepatic vascular bed, where dense fibrotic bands and parenchymal regeneration nodules increase intrahepatic resistance to portal venous blood flow. Splanchnic vasodilation worsens this pressure gradient, leading to congestive splenomegaly, hypersplenism with secondary sequestration of circulating platelets causing thrombocytopenia, portosystemic collateral formation including gastroesophageal varices, and third-space fluid accumulation resulting in ascites.
Asthenovegetative and dyspeptic syndromes represent the widespread systemic and functional gastrointestinal consequences of chronic liver disease. The asthenovegetative component centers on neuro-metabolic dysfunction, causing persistent fatigue, generalized physical weakness, emotional irritability, and disrupted sleep patterns. The dyspeptic component stems from secondary gastrointestinal dysmotility, altered bile acid delivery, and splanchnic venous congestion, presenting with anorexia, persistent nausea, postprandial fullness, flatulence, and vague abdominal discomfort.
4.5 Extrahepatic manifestations
Extrahepatic manifestations and multisystem associations provide vital diagnostic clues, often reflecting the unique immunological, metabolic, or systemic vascular mechanisms underlying specific etiologies of chronic liver disease.
Chronic hepatitis C virus (HCV) infection triggers a broad spectrum of extrahepatic immunologic and metabolic complications due to persistent immune activation and viral tropism for extrahepatic tissues. A major immunologic sequela is mixed cryoglobulinemia, wherein circulating immune complexes precipitate in cold environments, causing a leukocytoclastic vasculitis that manifests as purpura, arthralgias, and peripheral neuropathy. Renal involvement typically presents as membranoproliferative glomerulonephritis secondary to subendothelial deposition of these cryoglobulins. Dermatological associations include porphyria cutanea tarda—characterized by cutaneous fragility and blistering on sun-exposed skin due to altered heme biosynthesis—and oral or cutaneous lichen planus. Patients may also develop a Sjögren-like sicca syndrome with dry eyes and mouth. Systemically, chronic HCV infection increases the risk of metabolic disease, particularly type 2 diabetes mellitus due to induced insulin resistance, and carries an elevated incidence of B-cell non-Hodgkin lymphoma driven by chronic polyclonal B-cell stimulation.
Chronic hepatitis B virus (HBV) infection exhibits extrahepatic pathologies primarily mediated by circulating antigen-antibody immune complex deposition. Classical vasculitic involvement manifests as polyarteritis nodosa, a severe systemic necrotizing vasculitis of medium-sized arteries leading to hypertension, renal infarction, mononeuritis multiplex, and abdominal angina. Renal deposition of immune complexes can trigger glomerulonephritis, presenting as either membranous nephropathy or membranoproliferative patterns with overt proteinuria. During early or acute infectious phases, circulating immune complexes can precipitate a serum-sickness-like prodrome characterized by low-grade fever, urticarial skin rashes, and symmetrical polyarthralgias.
Autoimmune hepatitis (AIH) occurs within a broader genetic context of immune dysregulation, frequently clustering alongside other organ-specific or systemic autoimmune disorders. Thyroid autoimmunity, including Hashimoto's thyroiditis and Graves' disease, is common and necessitates routine thyroid function screening. Patients with AIH also show an increased prevalence of rheumatoid arthritis, type 1 diabetes mellitus, and systemic lupus erythematosus. Inflammatory bowel disease, particularly ulcerative colitis, exhibits a strong clinical overlap, especially in overlapping cholestatic syndromes like primary sclerosing cholangitis.
Wilson disease manifests with extrahepatic pathology driven by systemic toxic copper accumulation, primarily targeting the central nervous system and the cornea. Neurophenotypic presentation ranges from movement disorders—such as resting or action tremors, dystonia, dysarthria, and gait ataxia—to prominent psychiatric disturbances including personality changes, emotional lability, depression, and psychosis. Ocular examination using a slit lamp reveals Kayser-Fleischer rings, which appear as golden-brown or greenish copper deposits in Descemet's membrane along the limbus of the cornea, serving as a pathognomonic physical marker of systemic copper overload.
4.6 Clinical course by aetiology
Chronic hepatitis C is often nearly asymptomatic for decades, with fatigue the dominant complaint. Chronic hepatitis B has phases (immune tolerant, immune active, inactive carrier, and HBeAg-negative active hepatitis), and flares may occur with jaundice. Autoimmune hepatitis is more common in women, may present with high transaminases, hypergammaglobulinaemia, and sometimes an acute-onset picture. Metabolic hepatitis is usually associated with obesity, type 2 diabetes, and dyslipidaemia.
5. Diagnosis
Laboratory tests
• Liver biochemistry: ALT, AST, bilirubin, alkaline phosphatase, GGT, albumin, INR, and platelet count.
• Viral markers: HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, anti-HCV with HCV RNA and genotype, and anti-HDV with HDV RNA.
• Immunology: ANA, anti-smooth muscle antibodies, anti-LKM-1, and IgG level for autoimmune hepatitis.
• Metabolic screening: ceruloplasmin and urinary copper, ferritin and transferrin saturation, alpha-1 antitrypsin, glucose, and lipid profile.
Instrumental methods
• Abdominal ultrasound to assess liver size, echotexture, spleen, portal vein, and ascites.
• Non-invasive fibrosis assessment: transient elastography (FibroScan), and scores such as FIB-4 and APRI.
• Liver biopsy when the diagnosis is uncertain or when results change management, and in autoimmune or overlap disease.
• Upper gastrointestinal endoscopy to look for oesophageal varices in advanced fibrosis.
6. General Principles of Treatment
The main goals are to eliminate or suppress the cause, stop inflammation, prevent progression to cirrhosis, decompensation, and hepatocellular carcinoma, and improve quality of life. Treatment is individualised according to aetiology, activity, and stage.
6.1 Regimen and lifestyle
General non-pharmacological and protective measures form the foundation of management across all forms of chronic liver disease, aiming to limit further hepatocyte damage, optimize nutritional status, and reduce metabolic stress on the functional parenchyma.
Absolute and complete abstinence from alcohol is mandatory for every patient diagnosed with chronic liver disease, regardless of whether ethanol was the primary underlying etiology. Alcohol acts as a direct hepatocellular toxin and potent synergistic factor, markedly accelerating the rate of fibrotic progression, worsening systemic inflammation, and significantly increasing the risk of decompensation and hepatocellular carcinoma even at low levels of intake.
Pharmacological vigilance requires the strict avoidance of known hepatotoxic drugs, unstandardized herbal supplements, and unnecessary over-the-counter medications. Endogenous hepatic metabolic pathways are often compromised in chronic liver injury, altering drug clearance rates and increasing susceptibility to drug-induced liver injury. For analgesic and antipyretic control, acetaminophen (paracetamol) remains the preferred agent over nonsteroidal anti-inflammatory drugs—which can precipitate renal failure or variceal bleeding—but its total daily dose must be strictly limited to no more than two grams per day to avoid glutathione depletion and microvascular toxicity.
Nutritional management focuses on preserving lean muscle mass while mitigating fluid retention. A balanced, nutrient-dense diet delivering adequate total calories and high-quality protein (typically 1.2 to 1.5 grams per kilogram of body weight daily) is essential to combat hypermetabolism, prevent sarcopenia, and maintain immune function. Prolonged fasting should be avoided, and a late-evening carbohydrate-rich snack is encouraged to reduce overnight gluconeogenesis and muscle protein breakdown. In patients who have developed ascites or peripheral edema, dietary sodium intake must be restricted to approximately two grams (80 to 100 milliequivalents) per day to facilitate negative sodium balance and control fluid retention.
Targeted lifestyle modifications address metabolic stress and physical strain based on disease activity. In metabolic dysfunction-associated steatotic liver disease (MASLD and MASH), structured weight reduction targeting a seven to ten percent loss of total body weight, achieved through dietary adjustment and regular moderate aerobic exercise, is necessary to reduce hepatic steatosis, clear necroinflammation, and halt fibrotic remodeling. Conversely, during active inflammatory flares or severe exacerbations of chronic liver disease, heavy physical strain and strenuous exertion must be avoided to minimize splanchnic circulatory shunting and maintain adequate oxygenation and perfusion to the recovering liver tissue.
6.2 Aetiological treatment
Chronic hepatitis B. Treatment is indicated in patients with active disease, significant fibrosis, or cirrhosis, based on HBV DNA, ALT, and fibrosis stage. First-line drugs are the nucleos(t)ide analogues entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide, which have a high barrier to resistance and potently suppress viral replication. Pegylated interferon alfa is an alternative for selected patients with a finite course. Therapy is often long-term. Patients receiving immunosuppression or chemotherapy need prophylaxis against HBV reactivation.
Chronic hepatitis C. Direct-acting antivirals (DAAs) have transformed treatment. Pangenotypic regimens, such as sofosbuvir/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 8 to 12 weeks, achieve sustained virological response (cure) in more than 95% of patients with few adverse effects. Interferon-based therapy is no longer recommended. Sustained virological response is defined as undetectable HCV RNA 12 weeks after the end of treatment.
Chronic hepatitis D. Pegylated interferon alfa has been the traditional option. Bulevirtide, an entry inhibitor, is approved in Europe for chronic HDV with compensated liver disease. Underlying HBV should also be treated with a nucleos(t)ide analogue where indicated.
Autoimmune hepatitis. Treatment is immunosuppressive: prednisolone (or prednisone) to induce remission, usually combined with azathioprine for maintenance, with gradual steroid tapering. Treatment is usually long-term, and relapse after withdrawal is common. Budesonide may be used in selected non-cirrhotic patients, and second-line agents such as mycophenolate are used in intolerance or non-response.
Metabolic, alcoholic, and drug-induced hepatitis. The cornerstone is removing the cause: alcohol abstinence, withdrawal of the offending drug, and control of obesity, diabetes, and dyslipidaemia. Newer drugs are now available for MASH with fibrosis in some countries. In Wilson disease, copper chelators (such as D-penicillamine or trientine) or zinc are used; in haemochromatosis, phlebotomy.
6.3 Pathogenetic and symptomatic therapy
Symptomatic, supportive, and complication-directed therapies play an indispensable role in maintaining quality of life and managing the secondary sequelae of chronic liver disease, operating alongside etiology-specific interventions.
Ursodeoxycholic acid (UDCA) serves as a core therapeutic agent in cholestatic syndromes, chronic cholestatic liver diseases, and autoimmune overlap states. Mechanistically, UDCA works by expanding the hydrophilic bile acid pool, displacing toxic hydrophobic bile salts that accumulate within hepatocytes and cholangiocytes. This hydrophilic shift stimulates biliary bicarbonate and fluid secretion, stabilizes canalicular membranes, and exerts anti-apoptotic and immunomodulatory effects that protect intrahepatic biliary structures from chemical injury.
Symptomatic relief of cholestatic pruritus requires targeted interpleural and intraluminal binding agents to interrupt the enterohepatic circulation of pruritogenic compounds. Cholestyramine, a non-absorbable bile acid sequestrant, acts within the intestinal lumen to bind bile salts and prevent their reabsorption, facilitating their clearance in the feces. For patients who fail to tolerate or respond to cholestyramine, secondary agents such as rifampicin, which induces hepatic microsomal enzymes and downregulates bile acid synthesis, or opioid antagonists like naltrexone and the dual receptor agonist sertraline may be utilized to alter central neuro-sensory perception of itch.
The clinical utility of so-called hepatoprotective agents—including silymarin (milk thistle extract), essential phospholipids, ademetionine (S-adenosylmethionine), and L-ornithine L-aspartate—remains controversial. While these compounds are widely marketed for their antioxidant, membrane-stabilizing, or detoxification-supporting properties, high-quality, large-scale clinical trials demonstrate limited definitive evidence regarding their ability to alter hard clinical outcomes, reverse fibrosis, or reduce mortality. Consequently, hepatoprotectors must never replace definitive etiologic treatment, such as antiviral regimens, targeted immunosuppression, or abstinence from alcohol.
Management of decompensation complications focuses on controlling hemodynamic shifts and metabolic derangements. Ascites management pairs dietary sodium restriction with dual diuretic therapy, combining the aldosterone antagonist spironolactone with the loop diuretic furosemide to achieve effective natriuresis while preserving serum potassium balance. Prevention and control of variceal hemorrhage rely on reducing portal venous pressure using non-selective beta-blockers, such as propranolol, nadolol, or carvedilol, or performing direct structural obliteration via endoscopic band ligation. Finally, hepatic encephalopathy is managed by reducing neurotoxin generation and absorption within the gastrointestinal tract using the non-absorbable disaccharide lactulose—which acidifies the colonic lumen to trap ammonium ions as non-absorbable ammonium—often in combination with the non-absorbable antibiotic rifaximin to suppress ammonia-producing enteric flora.
6.4 Monitoring and prevention of complications
• Regular follow-up of ALT, bilirubin, albumin, INR, platelets, viral load, and elastography.
• Ultrasound surveillance for hepatocellular carcinoma, with or without alpha-fetoprotein, every six months in patients with cirrhosis and in selected high-risk HBV patients, even after viral cure.
• Vaccination against hepatitis A and hepatitis B (and other routine vaccines) in non-immune patients.
• Screening of household and sexual contacts.
• Referral for liver transplantation assessment in decompensated cirrhosis, refractory complications, or early hepatocellular carcinoma.
6.5 Prevention
Prevention includes universal hepatitis B vaccination, screening of blood and organ donors, safe injection and sterilisation practices, harm-reduction programmes, safe sex counselling, and prevention of mother-to-child transmission of HBV through vaccination, immunoglobulin, and antiviral therapy in pregnancy when indicated.
7. Prognosis
The prognosis depends on the cause, the stage of fibrosis, and the response to therapy. Cure of hepatitis C and long-term suppression of hepatitis B markedly reduce the risk of cirrhosis, liver failure, and cancer, though patients with advanced fibrosis still require lifelong surveillance. Untreated chronic hepatitis may progress to cirrhosis over years to decades, with a significant annual risk of decompensation and hepatocellular carcinoma.
8. Conclusion
Chronic hepatitis is a polyaetiological disease with a frequently silent course and non-specific symptoms, so diagnosis relies on a high index of suspicion, laboratory testing, and assessment of fibrosis. Modern treatment is centred on eliminating or controlling the cause, particularly with nucleos(t)ide analogues in hepatitis B and direct-acting antivirals in hepatitis C, supported by lifestyle measures, management of complications, vaccination, and long-term surveillance. Early detection and timely therapy can prevent progression to cirrhosis and liver cancer.
References
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170-1218.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol. 2015;63(4):971-1004.
Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the AASLD. Hepatology. 2020;72(2):671-722.
World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: WHO; 2024.
Kasper DL, Fauci AS, et al. Harrison's Principles of Internal Medicine. McGraw-Hill; current edition.
Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. Elsevier; current edition.